240 related articles for article (PubMed ID: 17485745)
21. A comprehensive approach to benefit-risk assessment in drug development.
Sarac SB; Rasmussen CH; Rasmussen MA; Hallgreen CE; Søeborg T; Colding-Jørgensen M; Christensen PK; Thirstrup S; Mosekilde E
Basic Clin Pharmacol Toxicol; 2012 Jul; 111(1):65-72. PubMed ID: 22356197
[TBL] [Abstract][Full Text] [Related]
22. Is having more preapproval data the best way to assure drug safety?
Garber AM
Health Aff (Millwood); 2008; 27(5):w371-3. PubMed ID: 18682442
[TBL] [Abstract][Full Text] [Related]
23. Developing new regulatory approaches to antimicrobial safety.
Tollefson L
J Vet Med B Infect Dis Vet Public Health; 2004; 51(8-9):415-8. PubMed ID: 15525377
[TBL] [Abstract][Full Text] [Related]
24. Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.
Alexander KP; Newby LK; Cannon CP; Armstrong PW; Gibler WB; Rich MW; Van de Werf F; White HD; Weaver WD; Naylor MD; Gore JM; Krumholz HM; Ohman EM; ;
Circulation; 2007 May; 115(19):2549-69. PubMed ID: 17502590
[TBL] [Abstract][Full Text] [Related]
25. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.
Wang Y; Bhattaram AV; Jadhav PR; Lesko LJ; Madabushi R; Powell JR; Qiu W; Sun H; Yim DS; Zheng JJ; Gobburu JV
J Clin Pharmacol; 2008 Feb; 48(2):146-56. PubMed ID: 18199891
[TBL] [Abstract][Full Text] [Related]
26. A quantitative approach to benefit-risk assessment of medicines - part 1: the development of a new model using multi-criteria decision analysis.
Mussen F; Salek S; Walker S
Pharmacoepidemiol Drug Saf; 2007 Jul; 16 Suppl 1():S2-S15. PubMed ID: 17546573
[TBL] [Abstract][Full Text] [Related]
27. Evidence-based medicine, systematic reviews, and guidelines in interventional pain management: part 6. Systematic reviews and meta-analyses of observational studies.
Manchikanti L; Datta S; Smith HS; Hirsch JA
Pain Physician; 2009; 12(5):819-50. PubMed ID: 19787009
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of care: the use of conceptual models to "see the forest and the trees" in planning outcomes studies.
Camann MA
Top Health Inf Manage; 2001 Nov; 22(2):10-4. PubMed ID: 11761787
[TBL] [Abstract][Full Text] [Related]
29. Patient-reported outcomes supporting anticancer product approvals.
Rock EP; Kennedy DL; Furness MH; Pierce WF; Pazdur R; Burke LB
J Clin Oncol; 2007 Nov; 25(32):5094-9. PubMed ID: 17991927
[TBL] [Abstract][Full Text] [Related]
30. How might cost effectiveness, quality of life, and outcomes data be used by government regulators?
Gatty B
Hosp Formul; 1994 Jan; 29(1):70, 69. PubMed ID: 10131268
[No Abstract] [Full Text] [Related]
31. The quandary of compounding for MCOs: administrative costs, risks, and waste.
Kaye T
Manag Care; 2003 Jan; 12(1):42-8. PubMed ID: 12575510
[TBL] [Abstract][Full Text] [Related]
32. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
Reeve LM
Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
[TBL] [Abstract][Full Text] [Related]
33. Finding, evaluating, and managing drug-related risks: approaches taken by the US Food and Drug Administration (FDA).
Weaver J; Grenade LL; Kwon H; Avigan M
Dermatol Ther; 2009; 22(3):204-15. PubMed ID: 19453344
[TBL] [Abstract][Full Text] [Related]
34. Application of the BRAT framework to case studies: observations and insights.
Levitan BS; Andrews EB; Gilsenan A; Ferguson J; Noel RA; Coplan PM; Mussen F
Clin Pharmacol Ther; 2011 Feb; 89(2):217-24. PubMed ID: 21178990
[TBL] [Abstract][Full Text] [Related]
35. The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process.
Roden DM; Temple R
Circulation; 2005 Apr; 111(13):1697-702. PubMed ID: 15811869
[No Abstract] [Full Text] [Related]
36. Surrogate endpoints and FDA's accelerated approval process.
Fleming TR
Health Aff (Millwood); 2005; 24(1):67-78. PubMed ID: 15647217
[TBL] [Abstract][Full Text] [Related]
37. The use of patient-reported outcome measures in the evaluation of medical products for regulatory approval.
Burke LB; Kennedy DL; Miskala PH; Papadopoulos EJ; Trentacosti AM
Clin Pharmacol Ther; 2008 Aug; 84(2):281-3. PubMed ID: 18580868
[TBL] [Abstract][Full Text] [Related]
38. Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke.
Feuerstein GZ; Zaleska MM; Krams M; Wang X; Day M; Rutkowski JL; Finklestein SP; Pangalos MN; Poole M; Stiles GL; Ruffolo RR; Walsh FL
J Cereb Blood Flow Metab; 2008 Jan; 28(1):217-9. PubMed ID: 17579658
[TBL] [Abstract][Full Text] [Related]
39. Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care.
Schiller LR; Johnson DA
Am J Gastroenterol; 2008 Apr; 103(4):815-9. PubMed ID: 18397418
[TBL] [Abstract][Full Text] [Related]
40. Impact of pharmacometric reviews on new drug approval and labeling decisions--a survey of 31 new drug applications submitted between 2005 and 2006.
Bhattaram VA; Bonapace C; Chilukuri DM; Duan JZ; Garnett C; Gobburu JV; Jang SH; Kenna L; Lesko LJ; Madabushi R; Men Y; Powell JR; Qiu W; Ramchandani RP; Tornoe CW; Wang Y; Zheng JJ
Clin Pharmacol Ther; 2007 Feb; 81(2):213-21. PubMed ID: 17259946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
